• 18 years or older

• Phase 1: Histologically confirmed locally advanced, inoperable, or metastatic tumor; Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma.

• For Phase 1 sub-studies: Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer

• Phase 2: Colorectal carcinoma

• No available standard of care therapy or participant is ineligible for standard of care therapy, except in CRC tumor type in which participant must have previously received all the following therapeutic agents:

‣ fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy

⁃ an anti-VEGF therapy

⁃ if wt-RAS (wt-KRAS and wt-NRAS), an anti-EGFR therapy

• Eastern Cooperative Oncology Group (ECOG) ≤1

• Body Weight ≥40 kg.

• Female participants of childbearing potential must have negative serum pregnancy test at screening; must not plan to become pregnant or have ova harvested or breastfeed while on study; must be willing to use specific contraception or avoid intercourse

• Male participants must be willing to use specific contraception and not plan to impregnate a female partner or donate sperm while on study

• Participant must be willing and able to provide written informed consent and to comply with the requirements of the trial